Cohance Life

Is Cohance Life overvalued or undervalued?

As of November 9, 2022, Cohance Life is considered overvalued with a high PE ratio of 100.54 and an EV to EBITDA of 71.77, despite similar metrics to its peer Suven Pharmaceuticals, and its recent performance has declined by -9.38% year-to-date compared to the Sensex's 5.56% gain.

As of 9 November 2022, Cohance Life has moved from expensive to very expensive, indicating a significant shift in valuation perception. The company is currently overvalued, as evidenced by its high PE ratio of 100.54, an EV to EBITDA ratio of 71.77, and a Price to Book Value of 15.87. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peer, Suven Pharmaceuticals Ltd., which has a similar PE ratio of 100.54 and an EV to EBITDA of 71.77, Cohance Life's valuation appears excessive. The company's return metrics, with a ROCE of 17.56% and ROE of 15.79%, do not justify such high valuation multiples. Furthermore, while the stock has outperformed the Sensex over the long term, recent performance shows a decline, with a year-to-date return of -9.38% compared to the Sensex's 5.56%. This reinforces the view that the stock is overvalued in the current market context.

Who are in the management team of Cohance Life?

As of March 2022, the management team of Cohance Life includes Venkateswarlu Jasti (Managing Director), J V Ramudu (Chairman), and several independent and non-executive directors, ensuring a diverse governance structure.

As of March 2022, the management team of Cohance Life includes the following individuals:<BR><BR>1. Venkateswarlu Jasti - Managing Director<BR>2. Deepanwita Chattopadhyay - Independent Director<BR>3. V Sambasiva Rao - Independent Director<BR>4. Jerry Jeyasingh - Non-Executive & Non-Independent Director<BR>5. Hanumantha Rao Kokkonda - Company Secretary<BR>6. D G Prasad - Independent Director<BR>7. J V Ramudu - Chairman & Non-Executive Director<BR>8. Shweta Jalan - Non-Executive Director<BR>9. U B Pravin Rao - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a company secretary, contributing to the governance and strategic direction of the company.

When is the next results date for Cohance Life?

No Upcoming Board Meetings

What is the bonus history of the Cohance Life?

Cohance Life issued a 1:1 bonus on September 25, 2020, with a record date of September 28, 2020, allowing shareholders to double their holdings by receiving an additional share for each share owned.

Cohance Life has a bonus history that includes a 1:1 bonus issue announced on September 25, 2020. The record date for this bonus was September 28, 2020. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time.

Has Cohance Life declared dividend?

Cohance Lifesciences Ltd has declared a 100% dividend, amounting to 5 per share, but the dividend yield is 0%. While the company has shown significant price appreciation over various periods, it has not consistently provided dividend returns.

Cohance Lifesciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 09 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.08%, with a dividend return of 0%, resulting in a total return of -19.08%.<BR><BR>Over the past year, the price return was 66.12%, with a dividend return of 0%, leading to a total return of 66.12%.<BR><BR>In the last 2 years, the price return was 122.25%, with a dividend return of 0%, resulting in a total return of 122.25%.<BR><BR>For the 3-year period, the price return was 115.92%, with a dividend return of 1.09%, culminating in a total return of 117.01%.<BR><BR>In the 4-year period, the price return was 103.18%, with a dividend return of 1.90%, leading to a total return of 105.08%.<BR><BR>Over the last 5 years, the price return was 539.98%, with a dividend return of 0%, resulting in a total return of 539.98%.<BR><BR>Overall, while Cohance Lifesciences Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods indicate significant price appreciation, particularly over the longer term, despite the lack of consistent dividend returns.

Who are the peers of the Cohance Life?

Cohance Life's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals, Pfizer, Emcure Pharma, and Wockhardt. Cohance Life has excellent management risk, while its 1-year return is 68.83%, significantly higher than Emcure Pharma's N/A return.

Peers: The peers of Cohance Life are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, Emcure Pharma, and Wockhardt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cohance Life, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Pfizer, and Emcure Pharma. Below Average growth is noted at Divi's Lab., Torrent Pharma, Gland Pharma, and Cohance Life, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Gland Pharma, J B Chemicals &, Cohance Life, and Pfizer, while Good is noted for Torrent Pharma and Emcure Pharma, and Below Average for Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 174.76%, while the lowest is Emcure Pharma, which has an N/A return. Cohance Life's 1-year return is 68.83%, which is significantly positive compared to the lowest peer. Additionally, Gland Pharma and Emcure Pharma have negative six-month returns.

What does Cohance Life do?

Cohance Lifesciences Ltd is a CDMO in the Pharmaceuticals & Biotechnology sector, providing services to major life science companies. As of March 2025, it reported net sales of 4,020 Cr and a net profit of 420 Cr, with a market cap of INR 40,632 Cr.

Overview:<BR>Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company in the Pharmaceuticals & Biotechnology industry, serving leading global life science and fine chemical majors.<BR><BR>History:<BR>Cohance Lifesciences Ltd was incorporated as Suven Pharmaceuticals Limited (SPL). The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,020 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 420 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 40,632 Cr (Large Cap) <BR><BR>Key Metrics:<BR>P/E: 152.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 15.79% <BR>Price to Book: 23.75 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Cohance Life?

The top shareholders of Cohance Life include Berhyanda Limited with 33.34%, mutual funds with 8.65%, foreign institutional investors at 7.38%, Jasti Property And Equity Holdings Private Limited with 6.59%, and individual investors holding 6.63%.

The top shareholders of Cohance Life include several key players. The majority shareholder is Berhyanda Limited, which holds a significant 33.34% of the company. Additionally, mutual funds collectively hold 8.65% through 28 schemes, while foreign institutional investors (FIIs) account for 7.38% with 167 different FIIs involved. The highest public shareholder is Jasti Property And Equity Holdings Private Limited, with a stake of 6.59%. Individual investors also have a notable presence, holding 6.63% of the shares.

How big is Cohance Life?

As of 24th July, Cohance Lifesciences Ltd has a market capitalization of 39,974.00 Cr, with recent net sales of 1,197.58 Cr and a net profit of 267.87 Cr. The latest balance sheet shows shareholder's funds of 2,050.66 Cr and total assets of 2,254.09 Cr.

As of 24th July, Cohance Lifesciences Ltd has a market capitalization of 39,974.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 1,197.58 Cr and a Net Profit of 267.87 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 2,050.66 Cr and Total Assets of 2,254.09 Cr.

Is Cohance Life technically bullish or bearish?

As of October 27, 2025, Cohance Life's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, Bollinger Bands, and moving averages, alongside a significant 1-year decline of -31.85%.

As of 27 October 2025, the technical trend for Cohance Life has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this conclusion include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. Additionally, the Dow Theory indicates a mildly bearish trend on both weekly and monthly levels. The stock's recent performance shows a significant decline, with a 1-year return of -31.85%, further supporting the bearish outlook.

How has been the historical performance of Cohance Life?

Cohance Life has demonstrated significant growth, with net sales rising to 2,608.50 Cr in March 2025 from 1,051.35 Cr in March 2024, and profit after tax increasing to 484.24 Cr. Despite a decline in operating profit margin, the company shows strong operational performance and a robust financial trajectory.

Answer:<BR>Cohance Life has shown significant growth in its historical performance, particularly in net sales and profit metrics. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Cohance Life reported net sales of 2,608.50 Cr, a substantial increase from 1,051.35 Cr in March 2024 and 1,340.33 Cr in March 2023. The total operating income mirrored this growth, reaching 2,608.50 Cr in March 2025, compared to 1,051.35 Cr in the previous year. The company's total expenditure also rose to 1,811.44 Cr in March 2025 from 645.54 Cr in March 2024, primarily driven by increased raw material costs and employee expenses. Operating profit (PBDIT) for March 2025 was reported at 866.27 Cr, up from 467.72 Cr in March 2024, indicating a strong operational performance despite a decline in operating profit margin to 30.56% from 38.6%. Profit before tax increased to 642.63 Cr in March 2025, while profit after tax reached 484.24 Cr, reflecting a growth from 300.28 Cr in March 2024. The company's total assets grew to 3,031.20 Cr in March 2025, up from 2,254.09 Cr in March 2024, with total liabilities also increasing to 3,031.20 Cr. Cash flow from operating activities was 288.00 Cr in March 2025, down from 358.00 Cr in March 2024, but the company ended with a net cash inflow of 38.00 Cr, compared to a net outflow of 17.00 Cr in the previous year. Overall, Cohance Life's financial trajectory indicates robust growth and operational scaling over the years.

Are Cohance Lifesciences Ltd latest results good or bad?

Cohance Lifesciences Ltd's latest Q3 FY26 results are poor, with a 76.01% decline in net profit to ₹36.72 crore and a 19.47% drop in revenue to ₹544.55 crore, reflecting significant operational challenges and contracting margins. The company needs to address these issues to stabilize its financial performance.

Cohance Lifesciences Ltd's latest results for Q3 FY26 indicate a troubling performance. The company reported a net profit of ₹36.72 crore, which is a significant decline of 76.01% year-on-year. Revenue also fell to ₹544.55 crore, down 19.47% compared to the same quarter last year. This marks the lowest quarterly revenue in recent periods and reflects ongoing operational challenges.<BR><BR>Additionally, both operating and PAT margins have contracted sharply, with operating margins dropping to 17.51% from 35.10% a year earlier, and PAT margins falling to just 5.33% from 22.70%. The overall financial performance suggests that the company is struggling with significant headwinds, including increased competition and pricing pressures in the contract development and manufacturing sector.<BR><BR>In summary, the latest results are decidedly poor, highlighting a critical need for the company to address its operational issues and stabilize its financial performance moving forward.

Should I buy, sell or hold Cohance Lifesciences Ltd?

Why is Cohance Lifesciences Ltd falling/rising?

As of 17-Mar, Cohance Lifesciences Ltd's stock price is Rs 302.00, up 2.63% today, reflecting positive short-term market sentiment. However, it has declined 42.86% year-to-date and 73.20% over the past year, with ongoing financial challenges and reduced investor participation.

As of 17-Mar, Cohance Lifesciences Ltd is experiencing a rise in its stock price, currently at Rs 302.00, reflecting an increase of Rs 7.75 or 2.63%. This upward movement can be attributed to its performance today, where the stock outperformed its sector by 2.35% and reached an intraday high of Rs 303.15, indicating positive market sentiment in the short term.<BR><BR>However, it is important to note that despite this recent rise, the stock has faced significant challenges over a longer period. Year-to-date, it has declined by 42.86%, and over the past year, it has generated a staggering return of -73.20%. The company has reported negative results in the last two consecutive quarters, with a notable drop in net sales by 16.9% compared to the previous four-quarter average and a significant fall in profit after tax by 61.2%.<BR><BR>Additionally, the stock's liquidity remains adequate for trading, but there has been a concerning decline in investor participation, with delivery volume falling by 47.45% against the five-day average. The company's financial health is also under scrutiny, as it has a low debt-to-equity ratio but has shown poor long-term growth, with operating profit decreasing at an annual rate of -1.40% over the last five years.<BR><BR>In summary, while the stock is currently rising due to short-term performance and market sentiment, it is essential to consider the broader context of its long-term struggles and negative financial indicators.

Why is Cohance Lifesciences Ltd falling/rising?

As of 18-Mar, Cohance Lifesciences Ltd's stock price is rising to 306.35, reflecting a 1.78% increase. Despite this short-term gain, the stock has a concerning long-term outlook with a year-to-date drop of 42.03% and a 72.96% decline over the past year.

As of 18-Mar, Cohance Lifesciences Ltd's stock price is rising, currently at 306.35, reflecting a change of 5.35 (1.78%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 1.51% today and has shown a consecutive gain over the last two days, rising a total of 4.11% during this period. Additionally, the stock reached an intraday high of Rs 309.4, indicating positive momentum.<BR><BR>Despite the recent gains, the stock has experienced significant declines over longer periods, with a year-to-date drop of 42.03% and a staggering 72.96% decrease over the past year. The company has faced challenges, including a decline in net sales and negative results in the last two quarters, which have contributed to its poor long-term growth outlook. However, the current rise in stock price may be influenced by its relatively high management efficiency, as indicated by a return on equity (ROE) of 21.44%, and a low debt-to-equity ratio, which suggests financial stability.<BR><BR>While the stock is currently experiencing a rise, the overall long-term performance remains concerning, as it has underperformed against benchmarks like the Sensex over various time frames. The recent upward movement could be seen as a short-term recovery amidst a backdrop of significant historical losses.

Why is Cohance Lifesciences Ltd falling/rising?

As of 19-Mar, Cohance Lifesciences Ltd's stock price is declining at 301.20, down 1.68%, following a trend reversal after two days of gains. The stock has significantly underperformed over the past year with a return of -74.24%, compounded by negative financial results and poor long-term growth prospects.

As of 19-Mar, Cohance Lifesciences Ltd's stock price is falling, currently at 301.20, reflecting a change of -5.15 (-1.68%). The stock has experienced a trend reversal, having fallen after two consecutive days of gains. Additionally, the stock touched an intraday low of Rs 295.55, which is a decrease of 3.53%. <BR><BR>In terms of performance, the stock has underperformed significantly over the past year, with a return of -74.24%, while the broader market, represented by the Sensex, has only declined by 1.65% in the same period. The company's financial health is also concerning, as it has reported negative results for the last two consecutive quarters, with a substantial decline in profit before tax (PBT) and profit after tax (PAT) compared to previous averages. <BR><BR>Moreover, the company's net sales have decreased by 1.98%, and its operating profit has grown at an annual rate of -1.40% over the last five years, indicating poor long-term growth prospects. The high percentage of pledged promoter shares adds further downward pressure on the stock price, especially in a falling market. <BR><BR>Overall, the combination of negative financial results, poor long-term growth, and high promoter pledges contributes to the stock's decline.

Why is Cohance Lifesciences Ltd falling/rising?

As of 20-Mar, Cohance Lifesciences Ltd's stock price is at 298.75, reflecting a decline of -0.18%. The stock has significantly underperformed over the past year with a -74.97% return, driven by deteriorating financial health and declining investor interest.

As of 20-Mar, Cohance Lifesciences Ltd's stock price is falling, currently at 298.75, reflecting a change of -0.55 (-0.18%). The stock has been underperforming, having lost -2.48% over the last two days and showing a performance today that is -1.88% lower than its sector. <BR><BR>In terms of longer-term performance, the stock has generated a staggering -74.97% return over the past year, significantly underperforming the BSE500 index, which has only declined by -2.38% in the same period. Additionally, the company's financial health appears to be deteriorating, with net sales falling by -1.98% and a reported PAT of Rs 40.19 crore, which has decreased by -61.2% compared to the previous four-quarter average. <BR><BR>Investor participation is also declining, as evidenced by a -44.73% drop in delivery volume compared to the five-day average. Furthermore, the company has declared negative results for the last two consecutive quarters, contributing to a sentiment that is likely driving the stock price down. The presence of 100% of promoter shares being pledged adds further downward pressure in a falling market, indicating a lack of confidence from insiders.<BR><BR>Overall, the combination of poor financial results, declining investor interest, and negative market sentiment is contributing to the ongoing decline in the stock price of Cohance Lifesciences Ltd.

Why is Cohance Lifesciences Ltd falling/rising?

As of 23-Mar, Cohance Lifesciences Ltd's stock price is rising to 301.00, reflecting a 0.58% increase after a trend reversal following previous declines. While there is short-term investor interest, the stock has significant long-term challenges, including a year-to-date decline of -43.05% and negative financial performance.

As of 23-Mar, Cohance Lifesciences Ltd's stock price is rising, currently at 301.00, with a change of 1.75 (0.58%) upward. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 4.15% today, indicating a relative strength compared to the broader market. Additionally, the stock has experienced a trend reversal, gaining after two consecutive days of decline, which may signal a shift in investor sentiment.<BR><BR>Despite opening with a loss of -2.54% and touching an intraday low of Rs 291.65, the stock's performance has improved throughout the day. Furthermore, there has been a rise in investor participation, with a delivery volume of 3.35 lacs on 20 March, which is a 3.9% increase compared to the 5-day average. This suggests growing interest from investors, which can contribute to upward price movement.<BR><BR>However, it is important to note that the stock has faced significant challenges over the longer term, including a year-to-date decline of -43.05% and a staggering -75.01% drop over the past year. The company's financial performance has also been concerning, with a -28.4% fall in profits and negative results declared for the last two consecutive quarters. Despite these negative factors, the current rise in stock price may reflect short-term trading dynamics rather than a fundamental recovery.

Why is Cohance Lifesciences Ltd falling/rising?

As of 24-Mar, Cohance Lifesciences Ltd's stock price is Rs 296.30, down 1.46%, with a year-to-date decline of 43.94% and a 74.69% drop over the past year. The stock's poor performance is driven by negative financial results, high volatility, and concerns over pledged promoter shares, contributing to a bearish market sentiment.

As of 24-Mar, Cohance Lifesciences Ltd's stock price is falling, currently at Rs 296.30, reflecting a decrease of Rs 4.4 or 1.46%. The stock has underperformed significantly over various periods, with a year-to-date decline of 43.94% and a staggering 74.69% drop over the past year. This poor performance is compounded by negative financial results, including a 61.2% fall in profit after tax compared to the previous four-quarter average and a decline in net sales of 1.98%. <BR><BR>Despite a brief opening gain of 2.1% today, the stock reached an intraday high of Rs 307 before falling to a low of Rs 293, indicating volatility and lack of sustained investor confidence. The stock is trading below all key moving averages, which suggests a bearish trend. Additionally, the company has declared negative results for the last two consecutive quarters, further contributing to the downward pressure on the stock price.<BR><BR>Moreover, the presence of 100% pledged promoter shares raises concerns among investors, particularly in a declining market, as it can exacerbate selling pressure. The overall market sentiment is also unfavorable, with the stock underperforming against the benchmark Sensex, which has declined by 2.63% over the past week. These factors collectively explain the current decline in Cohance Lifesciences Ltd's stock price.

Why is Cohance Lifesciences Ltd falling/rising?

As of 25-Mar, Cohance Lifesciences Ltd's stock price is currently at 305.75, reflecting a short-term gain despite a significant long-term decline of -73.14% over the past year and ongoing negative financial performance. The stock's recent rise is overshadowed by poor growth prospects and high risk factors.

As of 25-Mar, Cohance Lifesciences Ltd's stock price is rising, currently at 305.75, reflecting a change of 10.3 (3.49%) upward. This increase can be attributed to several factors. Firstly, the stock opened with a gain of 2% today and reached an intraday high of Rs 312.05, indicating positive momentum in the short term. Additionally, it outperformed its sector by 1.6%, suggesting that it is gaining traction relative to its peers.<BR><BR>Despite the positive movement today, it is important to note that the stock has faced significant challenges over the longer term. Over the past year, it has generated a return of -73.14%, and its profits have decreased by -28.4%. The company has also reported negative results for the last two consecutive quarters, with a substantial fall in PAT of -61.2% compared to the previous four-quarter average. Furthermore, the stock's performance has been below par in both the long term and near term, underperforming the BSE500 index over various periods.<BR><BR>While the stock is currently experiencing a rise, it is essential to consider the broader context of its poor long-term growth prospects, including a decline in net sales and a low operating profit growth rate. The high percentage of pledged promoter shares also adds a layer of risk, particularly in a falling market. Overall, while the stock is rising today, its long-term outlook remains concerning.

Which are the latest news on Cohance Life?